Funding to Support U.S. Market Launch in 2025 of Fast, Affordable, High-Precision NGS Solutions to Bring Precision Medicine Closer to Every Patient
SAN FRANCISCO, Jan. 28, 2025 /PRNewswire-PRWeb/ -- Foresee Genomics, an emerging next generation sequencing (NGS) solutions company focused on the small and medium-sized laboratory market, is excited to announce the successful close of a $1.3 million SAFE (Simple Agreement for Future Equity) round. This marks the company's final pre-revenue fundraising effort, setting the stage for the commencement of product sales in the United States later this year.
Since its founding in 2019, Foresee Genomics has spearheaded three successful clinical trials and pilot initiatives, two in Israel and one in the United States, and is now preparing for its commercial launch.
"This funding milestone is a testament to the market's need for more inclusive genomic solutions," said Margalit Tocher, CEO of Foresee Genomics. "We are grateful to our investors who share our firm belief in our mission. Together, we are working to bridge the gap between advanced technology and accessibility, empowering every lab to have access to data that will allow for precision medicine and enhanced patient outcomes across the globe."
Dr. Roi Feingersch, founder and CTO of Foresee Genomics, launched the company to address a significant need within the NGS market. "Currently, NGS is primarily used by large laboratory networks only, leaving few options for smaller to mid-size labs in rural areas. Our goal is to democratize access to advanced NGS technologies for all labs that may need the critical, timely information that these tests provide," said Feingersch.
According to the National Association of Community Health Centers (NACHC), a significant portion of patients in the U.S. receive care at community health centers. Foresee Genomics' technology can support these centers with advanced diagnostic tools which are crucial for delivering optimal healthcare services.
GoodPaper Ventures partner, Andrew Goodman, praised the initiative. "The Foresee Genomics solution empowers small and medium laboratories to deliver cost-effective next-generation sequencing results with minimal upfront investment. By enabling scalability and efficiency, it opens the door to high-quality genomic testing for a broader range of laboratories. At GoodPaper Ventures, we invest in market-leading companies that are poised for growth. Founder Roi Feingersch and CEO Margalit Tocher are exceptional leaders whose dedication, innovation, and results-driven approach continue to drive the company's success. We are proud to be a part of this exciting journey."
About Foresee Genomics
Foresee Genomics develops comprehensive solutions, including protocols, reagents, and bioinformatics tools, to make NGS accessible to small and medium-sized laboratories. Its mission is to enable these labs to perform high-accuracy genomic analysis independently, without the need for costly infrastructure or high minimum quantities. By streamlining the sequencing workflow and optimizing per-sample costs, Foresee Genomics helps laboratories provide timely, precise insights that support personalized patient care. For more information, please visit: https://www.foreseegenomics.com/
About GoodPaper Ventures
GoodPaper Ventures is a venture capital firm investing in founders with bold ideas that span industries and continents. By leveraging relationships, they effectively support founders and drive value for the company. They provide strategic guidance, connect founders with key industry players, and give other support to help companies succeed. For more information, please visit: https://www.goodpaperventures.com/
Media Contact
Margalit Tocher, Foresee Genomics, [email protected], https://www.foreseegenomics.com/
SOURCE Foresee Genomics
Share this article